ELELYSO

This brand name is authorized in United States. It is also authorized in Canada, Israel, New Zealand, South Africa, Turkey.

Active ingredients

The drug ELELYSO contains one active pharmaceutical ingredient (API):

1	Taliglucerase alfa UNII 0R4NLX88O4 - TALIGLUCERASE ALFA
	Taliglucerase alfa, a long term enzyme replacement therapy, is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. It is used for the treatment of patients with a confirmed diagnosis of Type 1 Gaucher disease.
	Read more about Taliglucerase alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELELYSO Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB11		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02425637
IL	מִשְׂרַד הַבְּרִיאוּת	7154
NZ	Medicines and Medical Devices Safety Authority	18441
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308267436
US	FDA, National Drug Code	0069-0106
ZA	Health Products Regulatory Authority	50/31/0316